

1 **Clinical features and outcomes of 2019 novel coronavirus-infected patients with high**
2 **plasma BNP levels**

3

4 Youbin Liu,MD,PHD,^{1,*.&} Dehui Liu, BS,^{1,*} Huafeng Song, BS,^{1,*} Chunlin Chen, BS, ¹.
5 *Mingfang Lv,MM, ¹Xing Pei,MM,¹Zhongwei Hu, BS, ¹Zhihui Qin, BS¹ Jinglong Li, BS, ^{1,*.&}

6

7 ¹Department of Cardiology, Guangzhou Eighth People's Hospital, Guangzhou, PR China

8 * These authors are equal to the work□

9 &Corresponding author:

10 Youbin Liu, MD; Department of Cardiology, Guangzhou Eighth People's Hospital,
11 Guangzhou medical university,8 huaying road, Baiyun district, Guangzhou city, Guangdong
12 province (510000), China(dryoubin@163.com)

13 Jinglong Li ; Department of Cardiology, Guangzhou Eighth People's Hospital, Guangzhou
14 medical university,8 huaying road, Baiyun district, Guangzhou city, Guangdong province
15 (510000), China(gz8ljl@163.com)

16

17 **Funding/Support:** None

18 **Acknowledgements:** The authors had full access to all of the data in the study and take
19 responsibility for the integrity of the data and the accuracy of the data analysis. All authors
20 have no conflict of interest to declare.

21

22

23 **Abstract**

24 **Aims**

25 To explore clinical features and outcome of 2019 novel coronavirus(2019-nCoV)-infected
26 patients with high BNP levels

27 **Methods and results**

28 Data were collected from patients' medical records, and we defined high BNP according to
29 the plasma BNP was above > 100 pg/mL. In total,34 patients with corona virus disease
30 2019(COVID-19)were included in the analysis. Ten patients had high plasma BNP level. The
31 median age for these patients was 60.5 years (interquartile range, 40-80y) , and 6/10 (60%)
32 were men. Underlying comorbidities in some patients were coronary heart disease (n=2,
33 20%) ,hypertesion (n=3 ,30%), heart failure (n=1,10%)and diabetes (n=2, 20%). Six (60%)
34 patients had a history of Wuhan exposure. The most common symptoms at illness onset in
35 patients were fever (n=7, 70%), cough (n=3, 30%), headache or fatigue (n=4,40%) . These
36 patients had higher aspartate aminotransferase(AST), troponin I, C reactive protein and lower
37 hemoglobin, and platelet count,compared with patients with normal BNP, respectively.
38 Compared with patients with normal BNP, patients with high BNP were more likely to
39 develop severe pneumonia, and receive tracheal cannula, invasive mechanical ventilation,
40 continuous renal replacement therapy, extracorporeal membrane oxygenation, and be
41 admitted to the intensive care unit. One patient with high BNP died during the study.

42 **Conclusion**

43 High BNP is a common condition among patients infected with 2019-nCoV. Patients with
44 high BNP showed poor clinical outcomes

45 **Keywords:** coronavirus, high BNP levels, clinical features,outcomes

46 INTRODUCTION

47 The 2019 novel coronavirus (2019-nCoV), a new fatal virus that emerged at the end of 2019,
48 is a growing public health concern worldwide (1). The findings from previous studies show
49 that some infected patients had abnormal laboratory test results, including blood cell counts ,
50 BNP and brain natriuretic peptide(BNP) and so on (2) (3). However, as a new coronavirus, we
51 still know little about whether 2019-nCoV is more likely to be harmful for these patients with
52 with high plasma BNP levels and the role of BNP in corona virus disease 2019(COVID-19).
53 More detailed investigations of the relationship between BNP and the clinical outcomes of
54 people infected with 2019-nCoV are urgently needed.

55 Brain natriuretic peptide (BNP), a member of a family of natriuretic peptides ,was first
56 identified in 1988 and discovered to be present in high concentrations in cardiac
57 tissues, , especially the ventricles (4). Initial studies showed that BNP levels were strongly
58 related to impaired left ventricular (LV) function (5). In recent years, BNP, as a valuable
59 clinical biochemical marker, has been widely used in the diagnosis, prognosis and therapeutic
60 effect evaluation of cardiovascular diseases such as acute coronary syndrome, right
61 ventricular dysfunction,pulmonary disease, diastolic dysfunction (6).However, plasma BNP
62 levels are affected by many factors. BNP is not only regulated by myocardial extension, but
63 also affected by factors such as tachycardia, epinephrine, thyroxine, vasoactive peptide and
64 infection and so on (7) . 2019-nCoV, as a new virus, although it mainly damages lung tissue,
65 some studies have found that it also has a destructive effect on the heart. A recent study
66 indicate N-Terminal pro-brain natriuretic peptide(NT-proBNP) has a prognostic value in

67 severe covid-19 patients (8).However, The role of BNP in COVID-19 patient is still
68 unknown..

69 This paper provides an overview of the clinical features of 2019-nCoV-infected patients
70 with high plasma BNP levels to provide insight into the prevention and treatment for these
71 patients.

72

73 **METHODS**

74 In total,34 patients with corona virus disease 2019(COVID-19)were included in analysis.
75 Patients were admitted to Guangzhou eighth people's hospital from January 20, 2020, to
76 February 24, 2020. Throat swab specimens were gathered from all patients after admission,
77 and Real-Time polymerase chain reaction were performed to detect 2019-nCoV ribonucleic
78 acid .All patients with COVID-19 were diagnosed based on the World Health Organization
79 interim guidelines(9). Unless otherwise specified, all values are the first data after admission,
80 and if the index was measured more than twice, we chose the highest value for analysis. High
81 BNP level was diagnosed if the plasma BNP were above the 99th percentile of the upper
82 reference limit (> 100 pg/mL)) using the tridge BNP test (Beckman Coulter Inc., Brea, CA,
83 USA). Pneumonia severity was defined according to the international guidelines for
84 community-acquired pneumonia(10). The epidemiological, laboratory, clinical and outcome
85 data are derived from the patient's electronic medical records. the ethics commissions of the
86 Guangzhou Eighth people's hospital has approved this study , with a waiver of informed
87 consent.

88 Continuous variables were expressed as mean \pm standard deviation for normally

89 distributed data or as median (interquartile range,IQR) for skewed distributions. Frequency
90 data were presented as proportions. Student's t test or the Mann–Whitney U test were
91 performed for continuous variables when appropriate, whereas differences in categorical
92 variables were assessed using the Chi-square test or Fisher's exact test. SPSS 25.0 (IBM Corp.
93 Armonk, NY, USA) were used to perform All analyses and a two-tailed p-value < 0.05 was
94 considered statistically significant.

95

96 **RESULTS**

97 **1. Epidemiological features of 2019-nCoV- infected patients with high BNP levels.**

98 A total of 34 patients were included and divided into two groups (high BNP group and
99 normal group) in the final analysis. Ten patients had high plasma BNP level (>100pg/mL).
100 The median age for these patients was 60.5 years (interquartile range, 40-80y) , and 6/10
101 (60%) were men. Underlying comorbidities in some patients were coronary heart disease
102 (n=2, 20%) ,hypertesion (n=3 ,30%), heart failure (n=1,10%)and diabetes (n=2, 20%). Six
103 (60%) patients had a history of wuhan exposure. The epidemiological characteristics of the
104 study participants are presented in Table 1.

105

106 **2. Clinical features and laboratory findings of 2019-nCoV-infected patients with high** 107 **BNP levels**

108 The most common symptoms at illness onset in patients were fever (n=7, 70%), cough (n=3,
109 30%), headache or fatigue (n=4,40%) . These patients had higher aspartate amino
110 transferase(AST),troponin I,C reactive protein and lower hemoglobin,and platelet

111 count, compared with patients with normal BNP, respectively. The clinical features and
112 selected laboratory findings of the study participants are presented in Table 2.

113 **3. Treatments and outcomes of 2019-nCoV-infected patients with high BNP levels**

114 Compared with patients with normal BNP, patients with high BNP were more likely to
115 develop severe pneumonia (80% vs 8.3%), and receive tracheal cannula (70% vs 0%),
116 invasive mechanical ventilation (40% vs 4.2%), continuous renal replacement therapy (40%
117 vs 0%), extracorporeal membrane oxygenation (30% vs 0%), and be admitted to the intensive
118 care unit (90% vs 8.3%). One patient with high BNP died during the study. The
119 epidemiological characteristics and outcomes of the study participants are presented in Table.

120

121 **DISCUSSION**

122 To the best of our knowledge, this is the first study systematically exploring clinical features
123 and outcomes of 2019 novel coronavirus-infected patients with high BNP (not NT-proBNP)
124 levels. Our results showed that 2019-nCoV infected patients with high plasma BNP levels
125 had worse clinical outcomes compared with patients with normal plasma BNP levels.

126 BNP and NT-proBNP, peptides produced by cardiomyocytes are widely used to guide
127 in diagnosis, prognosis and treatment of heart failure (11). It is well known that the level of
128 BNP in plasma is affected by many factors, such as inflammation and stress reaction and so
129 on (12). Therefore, it is very common for patients with other disease
130 are often accompanied with high plasma BNP level. Some studies have shown patients with
131 COVID-19 often had abnormal BNP/NT-proBNP in plasma (2) (3). However, by now, there is
132 no detailed investigation on clinical features and outcomes of 2019 novel
133 coronavirus-infected patients with high BNP levels. This study provides information on the

134 epidemiology and outcomes of 2019-nCoV-infected patients with high plasma BNP levels.
135 Most of patients with high BNP levels in our study were usually older and often had
136 pre-existing heart disease. High BNP level following 2019-nCoV infection is associated with
137 poor patient outcomes. These patients were more likely receive mechanical ventilation,
138 tracheal cannula, continuous renal replacement therapy, extracorporeal membrane
139 oxygenation and be admitted to the intensive care unit.

140 However, the reason why the outcomes of patients with high BNP were worse is unclear.
141 Inflammation and stress can stimulate BNP production and secretion from
142 cardiomyocytes(12).The level of BNP in plasma may reflect the severity of inflammation
143 and stress. This may partly explain why patients with high plasma BNP levels had a bad
144 outcomes. This study is limited by a relatively small number of samples from patients with
145 high BNP.These data contribute information to understanding clinical manifestations and
146 outcomes of 2019-nCoV infected patients.

147

148 REFERENCES

- 149 1. <https://www.who.int>. accessed March 15, 2020.
- 150 2. Lei Gao DJ, Xuesong Wen, Xiaocheng Cheng, Min Sun, Bin He. Prognostic value of
151 NT-proBNP in patients with severe COVID-19. *medRxiv preprint* 2020.
- 152 3. Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, He MA, Cheng LX, Huang K,
153 Zeng QT. [Clinical characteristics and outcomes of 112 cardiovascular disease patients
154 infected by 2019-nCoV]. *Zhonghua xin xue guan bing za zhi*. 2020 Mar 2;**48**(0):E004.
- 155 4. Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family. *Lancet*. 1997 May

156 3;**349**(9061):1307-1310.

157 5. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A,
158 McDonagh T, Mair J, Nieminen M, Francis G. Clinical applications of B-type natriuretic
159 peptide (BNP) testing. *European heart journal*. 2003 Oct;**24**(19):1710-1718.

160 6. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac
161 Dysfunction in Both Clinical and Forensic Medicine. *International journal of molecular*
162 *sciences*. 2019 Apr 12;**20**(8).

163 7. Maisel A, Mueller C, Adams K, Jr., Anker SD, Aspromonte N, Cleland JG, Cohen-Solal
164 A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda
165 M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M,
166 Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E. State of the art: using
167 natriuretic peptide levels in clinical practice. *European journal of heart failure*. 2008
168 Sep;**10**(9):824-839.

169 8. Lei Gao DJ, Xuesong Wen, Xiaocheng Cheng, Min Sun, Bin He. Prognostic value of
170 NT-proBNP in patients with severe COVID-19. *medRxiv 2020030720031575*;
171 2020.03.07.20031575.

172 9. WHO. Clinical management of severe acute respiratory infection when Novel
173 coronavirus (nCoV) infection is suspected: interim guidance.
174 [https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infe](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected)
175 [ction-when-novel-coronavirus-\(ncov\)-infection-is-suspected](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected). 2020.

176 10. Ranieri VM RG, Thompson BT, et al.; ARDS Definition Task Force. Acute respiratory
177 distress syndrome: the Berlin definition. *Jama*. 2012;**307**(23).

178 11. Volpe M, Battistoni A, Rubattu S. Natriuretic peptides in heart failure: Current
179 achievements and future perspectives. *International journal of cardiology*. 2019 Apr
180 15;**281**:186-189.

181 12. Matsuo A, Nagai-Okatani C, Nishigori M, Kangawa K, Minamino N. Natriuretic
182 peptides in human heart: Novel insight into their molecular forms, functions, and diagnostic
183 use. *Peptides*. 2019 Jan;**111**:3-17.

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201 **Table 1. The epidemiological features of 2019-nCoV-infected patients with**
202 **high BNP levels**

Variables	BNP>100 (N=10)	BNP≤100 (N=24)	P
Age (Y)	60.5(40-80)	38(33-52)	0.02*
Male, No(%)	6 (60)	12 (50)	0.72
Exposure history in Wuhan, No(%)	6 (60)	6(25)	0.11
Diabetes, No(%)	2 (20)	2(8.3)	0.56
Coronary heart disease, No(%)	2(20)	3(12.5)	0.62
Heart failure, No(%)	1(10)	0(0)	0.29
Arrhythmia, No(%)	1(10)	0(0)	0.29

203

204

205

206

207

208

209

210

211

212

213 **Table2.The clinical features and selected laboratory findings of 2019-nCoV-infected**
 214 **patients with high BNP levels**

Variables	Normal range	BNP>100 (N=10)	BNP≤100 (N=24)	<i>P</i>
Cough, No(%)	-	3(30)	15(62.5)	0.13
Fever, No(%)	-	7(70)	11(45.8)	0.27
Sore throat ,No(%)	-	1 (10)	6(25)	0.64
Headache or Fatigue, No(%)	-	4(40)	3(12.5)	0.16
Dyspnea, No(%)	-	2(20)	5(20.8)	1.0
Chest pain , No(%)	-	0(0)	0(0)	1.0
Palpitation, No(%)	-	0(0)	1(4.2)	1.0
Heart rate (bpm)	55-95	83(72-98)	87.5(80-97)	0.49
Temperature (°C)	36.3-37.3	36.9(36.5-38.3)	36.5(36-37)	0.09

Systolic pressure(mmHg)	90-139	134(121-145)	127(110-147)	0.38
White blood cell count (10E9/L)	4-10	5.6(5.0-10.2)	5.3(3.8-6.4)	0.45
Neutrophil count (10E9/L)	1.8-6.3	3.7(3.2-7.0)	3.1(2.1-4.3)	0.27
Lymphocytes count (10E9/L)	1.1-3.2	1.0(0.7-2.2)	1.3(1.1-1.9)	0.17
Hemoglobin, g/L	113-151	115.3±27.5	132.4±18	0.04*
Platelets count (10E9/L)	100-300	155.6±57.2	226.38±47.1	0.001*
C reactive protein (>10mg/L) , No(%)	<10	9(90)	5(20.8)	0.00*
Troponin I, (ug/L)	<0.03	0.08(0.02-0.29)	0.005(0.001-0.01)	0.00*
Creatinine, μmol/L	59~104	63.1(43.6-137.8)	60.5(51.4-77.0)	0.809
Brain natriuretic peptide (pg/mL)	<100	245.5(142.5-371.8)	18(9.8-36.3)	0.00*
Aspartate aminotransferase (U/L)	13-35	24.7(18.95-37.6)	17.6(13.4-19.95)	0.02*

Alanine aminotransferase (U/L)	7-40	16.3(9.8-24.8)	16.6(12.8-24.5)	0.59
Myoglobin (ug/L)	17.4-105.7	32.8(15.8-156.2)	15.1(11-20.9)	0.001*
Creatine kinase (U/L)	50-310	48(34.8-83.8)	56.2(42.3-78.3)	0.86
D-dimer(mg/L)	<1000	1765(667.5-6085)	990(660-1280)	0.15
Bilateral pneumonia No(%)	--	9(90)	14(58.3)	0.11

215

216

217

218

219

220

221

222

223

224

225

226

227

228 **Table 3. Treatments and outcomes of 2019-nCoV-infected patients with**
229 **high BNP levels**

Variables	BNP>100 (N=10)	BNP≤100 (N=24)	<i>P</i>
Tracheal cannula, No(%)	7(70)	0(0)	0.00*
Invasive mechanical ventilation, No(%)	4(40)	1(4.2)	0.02*
Vasopressor therapy, No(%)	2(20)	0(0)	0.08
CRRT, No(%)	4(40)	0(0)	0.005*
ECMO, No(%)	3(30)	0(0)	0.02*
Acute respiratory distress syndrome, No(%)	2(20)	0(0)	0.08
Severe pneumonia, No(%)	8(80)	2(8.3)	0.00*
Admission to ICU, No(%)	9(90)	2 (8.3)	0.00*
Death, No(%)	1(10)	0 (0)	0.29

230

231

232

233

234

235